Original Article | Published:

HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions

The Pharmacogenomics Journal volume 17, pages 501505 (2017) | Download Citation

Abstract

Clindamycin causes cutaneous adverse drug reactions (cADRs), sometimes with the mechanisms of pathogenicity or risk factors unknown. This study aims to assess whether HLA alleles are associated with clindamycin-related cADRs in the Han Chinese population. We performed an association study of 12 subjects with clindamycin-related cADRs, 279 controls and 26 clindamycin-tolerant subjects. Subjects who received clindamycin through intravenous drip were analyzed separately. Unbiased, in silico docking was conducted. We found 6 out of 12 clindamycin-induced cADR patients carried HLA-B*51:01, and all of them received clindamycin via intravenous drip (6/9). The carrier frequency of HLA-B*51:01 is significantly higher compared with the control group (P=0.0006; OR=9.731, 95% CI: 2.927–32.353) and the clindamycin-tolerant group (OR=24.000, 95% CI: 3.247–177.405). In silico docking showed clindamycin is potentially more stable inside HLA-B*51:01 protein. Our results suggested, for the first time, that HLA-B*51:01 is a risk allele for clindamycin-related cADRs in Han Chinese, especially when clindamycin is administered via intravenous drip.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , . Lincomycin clindamycin and their applications. Appl Microbiol Biotechnol 2004; 64: 455–464.

  2. 2.

    . Update on clindamycin in the management of bacterial, fungal and protozoal infections. Expert Opin Pharmacother 2007; 8: 2401–2444.

  3. 3.

    . Clindamycin–efficacy and toxicity. West J Med 1975; 122: 526–530.

  4. 4.

    The US Food and Drug Administration (2015). Drug label. .

  5. 5.

    , , , . Adverse reactions and safety of clindamycin. Advers Drug React J 2003; 5: 83–87.

  6. 6.

    , , , , , . Analysis of 215 cases adverse reaction caused by clindamycin. Acad J Guangdong Coll Pharm 2006; 2: 80–81.

  7. 7.

    , , , , . Clinical and bacteriological studies with clindamycin. Br Med J 1970; 2: 703–704.

  8. 8.

    , , , . Clindamycin in the treatment of serious anaerobic infections. Ann Intern Med 1973; 78: 853–859.

  9. 9.

    , , . Clindamycin hypersensitivity appears to be rare. Ann Allergy Asthma Immunol 1999; 82: 443–445.

  10. 10.

    , . Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37: 833–838.

  11. 11.

    , , , , , et al. Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organ J 2013; 6: 18.

  12. 12.

    , , , , , et al. A marker for Stevens–Johnson syndrome. Nature 2005; 428: 486.

  13. 13.

    , , , , , et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49: 2087–2091.

  14. 14.

    , , , , , et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75: 579–582.

  15. 15.

    , , , , , et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51: 926–930.

  16. 16.

    , , , , . Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011; 29: 290–293.

  17. 17.

    , , , , , et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011; 97: 190–197.

  18. 18.

    , , , , , et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20: 1034–1041.

  19. 19.

    , , , , , et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134–1143.

  20. 20.

    The US Food and Drug Administration (2015). Drug .

  21. 21.

    The US Food and Drug Administration (2015). Drug .

  22. 22.

    , , , , . Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol 2013; 25: 81–89.

  23. 23.

    US National Library of Medicine National Institutes of Health (2015). dbMHC Home .

  24. 24.

    , , , , , et al. SouthernHan Chinese from People's Republic of China. Anthropology/human genetic diversitypopulation reports. In: Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference, Volume I. IHWG Press: Seattle, 2007: 616–617.

  25. 25.

    , , , , , et al. Single Locus Polymorphism of Classical HLA Genes. In: (ed) Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press: Seattle, 2007, pp 653–704.

  26. 26.

    , , , , , et al. HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population. Pharmacogenomics 2014; 15: 1461–1469.

  27. 27.

    , , , , , . Nonstandard peptide binding revealed by crystal structures of Hla-B5101 complexed with HIV immunodominant epitopes. J Immunol 2000; 165: 3260–3267.

  28. 28.

    , , , , , et al. The protein data bank. Nucleic Acids Res 2000; 28: 235–242.

  29. 29.

    , , . Nakamura announcing the worldwide Protein Data Bank. Nat Struct Biol 2003; 10: 980.

  30. 30.

    , , , , , et al. Crystal structures of two peptide-HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype. Acta Crystallogr 2006; 62: 1300–1310.

  31. 31.

    , , , , . Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000; 405: 537–543.

  32. 32.

    , , , , , et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180–4185.

  33. 33.

    Shanghai Bureau of Statistics (2015). Statistical data .

  34. 34.

    , , , , . Adverse cutaneous drug reactions: eight year assessment in hospitalized patients. J Res Med Sci 2014; 19: 720–725.

  35. 35.

    , , Chinese from Hong Kong, People's Republic of China. Anthropology/human genetic diversity population reports. In: (ed) Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference, Volume I. IHWG Press: Seattle, 2007, pp 617–618.

  36. 36.

    , , , , , , . Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol 2011; 109: 42–46.

  37. 37.

    , , , , , et al. Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications. Sci Rep 2014; 4: 5981.

  38. 38.

    , , , , , , . Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol 2012; 74: 971–977.

  39. 39.

    , , , , , , . Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013; 43: 1246–1255.

  40. 40.

    , , , , . In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 2003; 31: 878–887.

  41. 41.

    , , , , . Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–272.

  42. 42.

    , , , , , et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009; 9: 23–33.

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grants 81472873, 81071287 and 31371274), Science and Technology Commission of Shanghai Municipality (14DJ1400100), Scientific and Technological Research in Open Collaborative Projects of Henan Province (152106000044) and HHS|NIH|U.S. National Library of Medicine (4R00LM009826-03). We thank the patients for their cooperation. The work was done in Shanghai, China.

Author information

Author notes

    • Y Yang
    •  & S Chen

    These authors contributed equally to this work.

    • J Xuan

    Current address: National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA.

Affiliations

  1. Children’s Hospital & Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    • Y Yang
    • , H Zhu
    • , J Xuan
    • , J Mu
    • , L He
    •  & Q Xing
  2. Huashan Hospital, Fudan University, Shanghai, China

    • S Chen
    • , F Yang
    •  & X Luo
  3. Department of Pharmacology, School of Medicine, Zhengzhou University, Zhengzhou, China

    • L Zhang
  4. Children’s Hospital Informatics Program, Boston, MA, USA

    • G Alterovitz
  5. Center for Biomedical Informatics, Harvard Medical School, Boston, MA, USA

    • G Alterovitz
  6. Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA

    • G Alterovitz
  7. School of Pharmacy, Fudan University, Shanghai, China

    • X Yang
  8. University of Arkansas at Little Rock/University of Arkansas for Medical Sciences Joint Bioinformatics Program, Little Rock, AR, USA

    • H Luo

Authors

  1. Search for Y Yang in:

  2. Search for S Chen in:

  3. Search for F Yang in:

  4. Search for L Zhang in:

  5. Search for G Alterovitz in:

  6. Search for H Zhu in:

  7. Search for J Xuan in:

  8. Search for X Yang in:

  9. Search for H Luo in:

  10. Search for J Mu in:

  11. Search for L He in:

  12. Search for X Luo in:

  13. Search for Q Xing in:

Competing interests

The authors declare no conflict of interest.

Corresponding authors

Correspondence to X Luo or Q Xing.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/tpj.2016.61

Further reading